SLC5A2 and chronic kidney disease: Among patients with ASCVD or CKD, Black race was associated with a lower rate of SGLT2 inhibitor use (aOR, 0.89 [95% CI, 0.82-0.97] for CKD; aOR, 0.84 [95% CI, 0.81-0.87] for ASCVD).